Objectives
Primary
- Estimate the rate of molecular response (MR) to tebentafusp in each of the 2 cohorts:
- Cutaneous melanoma with MRD
- Uveal melanoma with MRD
Secondary
- Evaluate the efficacy of Tebentafusp in each cohort
- Assess the safety and tolerability of tebentafusp in MRD
- Assess the rate of molecular relapse in both cohorts
- Characterise pharmacodynamic changes with tebentafusp treatment
- Preliminary evaluation of response rate in gp100 expressing melanoma
Tertiary/Exploratory
- Characterise pharmacodynamic changes with tebentafusp treatment
- Preliminary evaluation of response rate in gp100 expressing melanoma
